Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 12/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462739 | 0.89 | CTSS (0.49) | CTSKCTSSCYP3A4CYP2C9MMP1 | |
| SCHEMBL7046177 | 0.89 | CTSS (0.49) | CTSKCTSSCYP3A4CYP2C9MMP1 | |
| SCHEMBL6061690 | 0.89 | CTSS (0.49) | CTSKCTSSCYP3A4CYP2C9MMP1 | |
| SCHEMBL6063879 | 0.86 | CTSS (0.49) | CTSKCTSSCYP3A4CYP2C9CTSL | |
| SCHEMBL5416092 | 0.84 | CTSS (0.48) | CTSKCTSSCYP3A4CYP2C9 | |
| SCHEMBL6467112 | 0.83 | CTSK (0.47) | CTSKCTSSCYP3A4CYP2C9CTSL | |
| SCHEMBL7047000 | 0.83 | CTSS (0.42) | CTSKCTSSMMP1MMP3MMP9 | |
| SCHEMBL5520898 | 0.81 | CTSS (0.53) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL6061583 | 0.80 | PRSS8 (0.51) | CTSKCTSSMMP1MMP3CTSL | |
| SCHEMBL5945997 | 0.80 | CTSS (0.50) | CTSSCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSK 32/4885CTSS 9/4885CYP3A4 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.